Transcription factor KLF9 suppresses the growth of hepatocellular carcinoma cells in vivo and positively regulates p53 expression

Cancer Letters

Volumn 355, Issue 1, 2014, Pages 25-33

  Sun, Jiabin ^a   Wang, Boshi ^b   Liu, Yun ^b   Zhang, Li ^b   Ma, Aihui ^b   Yang, Zhaojuan ^b   Ji, Yuhua ^a   Liu, Yongzhong ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI CANCER INSTITUTE   (China)

Author keywords

Apoptosis; Hepatocellular carcinoma; KLF9; P53 protein; Transcriptional regulation

Indexed keywords

CYCLOHEXIMIDE; PROTEIN P53; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR KLF9; UNCLASSIFIED DRUG; KLF9 PROTEIN, HUMAN; KRUPPEL LIKE FACTOR; TP53 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN STABILITY; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; BINDING SITE; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GENETICS; HEPG2 CELL LINE; LIVER TUMOR; METABOLISM; NUDE MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; TIME;

ANIMALS; APOPTOSIS; BINDING SITES; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; LIVER NEOPLASMS; MALE; MICE, INBRED BALB C; MICE, NUDE; PROMOTER REGIONS, GENETIC; PROTEIN STABILITY; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84907965660     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.09.022     Document Type: Article

References (32)

1. Imataka H., Sogawa K., Yasumoto K., Kikuchi Y., Sasano K., Kobayashi A., et al. Two regulatory proteins that bind to the basic transcription element (BTE), a GC box sequence in the promoter region of the rat P-4501A1 gene. EMBO J. 1992, 11:3663-3671.
2. Kaczynski J., Cook T., Urrutia R. Sp1- and Kruppel-like transcription factors. Genome Biol 2003, 4:206-214.
3. McConnell B.B., Yang V.W. Mammalian Kruppel-like factors in health and diseases. Physiol. Rev 2010, 90:1337-1381.
4. Fernandez-Zapico M.E., Mladek A., Ellenrieder V., Folch-Puy E., Miller L., Urrutia R. An mSin3A interaction domain links the transcriptional activity of KLF11 with its role in growth regulation. EMBO J. 2003, 22:4748-4758.
5. Pang Y.P., Kumar G.A., Zhang J.S., Urrutia R. Differential binding of Sin3 interacting repressor domains to the PAH2 domain of Sin3A. FEBS Lett 2003, 548:108-112.
6. Bonett R.M., Hu F., Bagamasbad P., Denver R.J. Stressor and glucocorticoid-dependent induction of the immediate early gene kruppel-like factor 9: implications for neural development and plasticity. Endocrinology 2009, 150:1757-1765.
7. Pabona J.M., Simmen F.A., Nikiforov M.A., Zhuang D., Shankar K., Velarde M.C., et al. Kruppel-like factor 9 and progesterone receptor coregulation of decidualizing endometrial stromal cells: implications for the pathogenesis of endometriosis. J. Clin. Endocrinol. Metab 2012, 97:E376-E392.
8. Pabona J.M., Velarde M.C., Zeng Z., Simmen F.A., Simmen R.C. Nuclear receptor co-regulator Kruppel-like factor 9 and prohibitin 2 expression in estrogen-induced epithelial cell proliferation in the mouse uterus. J. Endocrinol 2009, 200:63-73.
9. Pei H., Yao Y., Yang Y., Liao K., Wu J.R. Kruppel-like factor KLF9 regulates PPARgamma transactivation at the middle stage of adipogenesis. Cell Death Differ 2011, 18:315-327.
10. Sporl F., Korge S., Jurchott K., Wunderskirchner M., Schellenberg K., Heins S., et al. Kruppel-like factor 9 is a circadian transcription factor in human epidermis that controls proliferation of keratinocytes. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:10903-10908.
11. Kang L., Lu B., Xu J., Hu H., Lai M. Downregulation of Kruppel-like factor 9 in human colorectal cancer. Pathol. Int 2008, 58:334-338.
12. Ying M., Sang Y., Li Y., Guerrero-Cazares H., Quinones-Hinojosa A., Vescovi A.L., et al. Kruppel-like family of transcription factor 9, a differentiation-associated transcription factor, suppresses Notch1 signaling and inhibits glioblastoma-initiating stem cells. Stem Cells 2011, 29:20-31.
13. Venook A.P., Papandreou C., Furuse J., de Guevara L.L. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 2010, 15(Suppl. 4):5-13.
14. Kremer-Tal S., Narla G., Chen Y., Hod E., DiFeo A., Yea S., et al. Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. J. Hepatol 2007, 46:645-654.
15. Sirach E., Bureau C., Peron J.M., Pradayrol L., Vinel J.P., Buscail L., et al. KLF6 transcription factor protects hepatocellular carcinoma-derived cells from apoptosis. Cell Death Differ 2007, 14:1202-1210.
16. Li Q., Gao Y., Jia Z., Mishra L., Guo K., Li Z., et al. Dysregulated Kruppel-like factor 4 and vitamin D receptor signaling contribute to progression of hepatocellular carcinoma. Gastroenterology 2012, 143:799-810. e1-e2.
17. Fu D.Z., Cheng Y., He H., Liu H.Y., Liu Y.F. The fate of Kruppel-like factor 9-positive hepatic carcinoma cells may be determined by the programmed cell death protein 5. Int. J. Oncol 2014, 44:153-160.
18. Ellenrieder V., Buck A., Harth A., Jungert K., Buchholz M., Adler G., et al. KLF11 mediates a critical mechanism in TGF-beta signaling that is inactivated by Erk-MAPK in pancreatic cancer cells. Gastroenterology 2004, 127:607-620.
19. Xiong Y., Svingen P.A., Sarmento O.O., Smyrk T.C., Dave M., Khanna S., et al. Differential coupling of KLF10 to Sin3-HDAC and PCAF regulates the inducibility of the FOXP3 gene. Am. J. Physiol. Regul. Integr. Comp. Physiol 2014, 307:R608-R620.
20. Zhang J.S., Moncrieffe M.C., Kaczynski J., Ellenrieder V., Prendergast F.G., Urrutia R. A conserved alpha-helical motif mediates the interaction of Sp1-like transcriptional repressors with the corepressor mSin3A. Mol. Cell. Biol 2001, 21:5041-5049.
21. Mannava S., Zhuang D., Nair J.R., Bansal R., Wawrzyniak J.A., Zucker S.N., et al. KLF9 is a novel transcriptional regulator of bortezomib- and LBH589-induced apoptosis in multiple myeloma cells. Blood 2012, 119:1450-1458.
22. Shen P., Sun J., Xu G., Zhang L., Yang Z., Xia S., et al. KLF9, a transcription factor induced in flutamide-caused cell apoptosis, inhibits AKT activation and suppresses tumor growth of prostate cancer cells. Prostate 2014, 74:946-958.
23. Bieker J.J. Kruppel-like factors: three fingers in many pies. J. Biol. Chem 2001, 276:34355-34358.
24. Lavin M.F., Gueven N. The complexity of p53 stabilization and activation. Cell Death Differ 2006, 13:941-950.
25. Ashcroft M., Vousden K.H. Regulation of p53 stability. Oncogene 1999, 18:7637-7643.
26. Sax J.K., El-Deiry W.S. p53 downstream targets and chemosensitivity. Cell Death Differ 2003, 10:413-417.
27. Sadot E., Geiger B., Oren M., Ben-Ze'ev A. Down-regulation of beta-catenin by activated p53. Mol. Cell. Biol 2001, 21:6768-6781.
28. Cagatay T., Ozturk M. P53 mutation as a source of aberrant beta-catenin accumulation in cancer cells. Oncogene 2002, 21:7971-7980.
29. Zucker S.N., Fink E.E., Bagati A., Mannava S., Bianchi-Smiraglia A., Bogner P.N., et al. Nrf2 amplifies oxidative stress via induction of Klf9. Mol. Cell 2014, 53:916-928.
30. Kim G.P., Mahoney M.R., Szydlo D., Mok T.S., Marshke R., Holen K., et al. An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma. Invest. New Drugs 2012, 30:387-394.
31. Chen K.F., Yeh P.Y., Hsu C., Hsu C.H., Lu Y.S., Hsieh H.P., et al. Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway. J. Biol. Chem 2009, 284:11121-11133.
32. Chen K.F., Yu H.C., Liu C.Y., Chen H.J., Chen Y.C., Hou D.R., et al. Bortezomib sensitizes HCC cells to CS-1008, an antihuman death receptor 5 antibody, through the inhibition of CIP2A. Mol. Cancer Ther 2011, 10:892-901.